HEXACHLOROPHENE - Generic Drug Details

What are the generic drug sources for hexachlorophene and what is the scope of patent protection?

Hexachlorophene is the generic ingredient in sixteen branded drugs marketed by Vestal Labs, Xttrium, Huntington Labs, Sanofi Aventis Us, Bayer Pharms, Arbrook, Dial, Calgon, Becton Dickinson, Prof Dspls, Davis And Geck, and 3M, and is included in seventeen NDAs. Additional information is available in the individual branded drug profile pages.

Summary for HEXACHLOROPHENE

US Patents:	0
Tradenames:	16
Applicants:	12
NDAs:	17
Drug Master File Entries:	7
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	1
DailyMed Link:	HEXACHLOROPHENE at DailyMed

Recent Clinical Trials for HEXACHLOROPHENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Natividad Medical Center	N/A

See all HEXACHLOROPHENE clinical trials

Medical Subject Heading (MeSH) Categories for HEXACHLOROPHENE

Anti-Infective Agents, Local

Anatomical Therapeutic Chemical (ATC) Classes for HEXACHLOROPHENE

D08AE	Phenol and derivatives
D08A	ANTISEPTICS AND DISINFECTANTS
D08	ANTISEPTICS AND DISINFECTANTS
D	Dermatologicals

US Patents and Regulatory Information for HEXACHLOROPHENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Huntington Labs	GERMA-MEDICA	hexachlorophene	SOLUTION;TOPICAL	017412-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Arbrook	GAMOPHEN	hexachlorophene	SOAP;TOPICAL	006270-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Davis And Geck	PRE-OP II	hexachlorophene	SPONGE;TOPICAL	017433-002	Approved Prior to Jan 1, 1982	AT	RX	Yes	No
Becton Dickinson	E-Z SCRUB	hexachlorophene	SPONGE;TOPICAL	017452-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Xttrium	TURGEX	hexachlorophene	AEROSOL;TOPICAL	018375-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	PHISOHEX	hexachlorophene	EMULSION;TOPICAL	006882-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Calgon	SEPTI-SOFT	hexachlorophene	SOLUTION;TOPICAL	017460-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Hexachlorophene Market Dynamics, Financial Trajectory, Patents, and FDA Status

Last updated: September 2, 2026

Hexachlorophene has no material branded pharmaceutical market in the United States. Its commercial decline resulted from neurotoxicity concerns, severe restrictions on infant and routine antiseptic use, replacement by chlorhexidine and povidone-iodine, and the expiration of legacy intellectual-property rights. Public companies do not report meaningful standalone hexachlorophene revenue, and no active U.S. exclusivity appears to support a premium-priced product.

What is the current market status of hexachlorophene?

Hexachlorophene is a chlorinated bisphenol antiseptic formerly used in topical washes, surgical scrubs, and dermatological products. The best-known U.S. product was pHisoHex, a 3% hexachlorophene cleanser.

The U.S. market contracted sharply after FDA actions in the early 1970s. The agency restricted hexachlorophene after reports of central nervous system toxicity, including encephalopathy in infants exposed to concentrated or repeated products. FDA required prominent warnings and limited use to situations where the expected benefit justified the risk (U.S. Food and Drug Administration [FDA], 1972).

Current commercial characteristics include:

Market factor	Current position
U.S. branded product	Historical products such as pHisoHex are discontinued or no longer materially marketed
Prescription status	Historical prescription topical drug
OTC status	Not an unrestricted OTC antiseptic ingredient
Hospital demand	Replaced largely by chlorhexidine, povidone-iodine, and alcohol-based products
Consumer demand	Minimal in the United States
Biosimilar exposure	None
Generic exposure	Theoretical, but limited by weak demand and safety concerns
Public revenue disclosure	No meaningful standalone revenue reported
Patent-driven pricing power	None apparent from the age of the molecule and product history

Hexachlorophene can still appear in historical formularies, non-U.S. products, specialty supplies, or limited institutional channels. Those channels do not constitute a large or transparent global pharmaceutical market.

When did hexachlorophene lose exclusivity?

Hexachlorophene lost practical market exclusivity decades ago. The active ingredient was introduced before the modern U.S. patent regime, and any original composition or basic-use patents would have expired long before the current period.

The commercial protection profile is therefore different from that of a modern drug:

• No viable composition-of-matter exclusivity remains.
• Legacy formulation patents, if any existed, would have expired.
• Method-of-use claims would generally be vulnerable because antiseptic uses were publicly known for decades.
• Manufacturing processes for a mature small molecule are unlikely to create a meaningful barrier to entry.
• Regulatory restrictions, product liability, and weak demand are more important than patent barriers.

For a small-molecule topical product, a later formulation patent could theoretically extend protection. There is no clear evidence of a commercially important, unexpired U.S. formulation patent supporting hexachlorophene sales.

What patents protect hexachlorophene?

No active U.S. patent estate appears to protect hexachlorophene as a commercially significant pharmaceutical product.

A modern freedom-to-operate review would examine four categories:

Patent category	Hexachlorophene position
Active ingredient	Historical chemistry; practical patent term expired
Salt, crystal, or polymorph	Not a material feature of the legacy product
Topical formulation	Any historical claims are likely expired
Method of use	Long-public antiseptic uses create substantial prior-art barriers
Manufacturing process	Potentially relevant only to a particular process, not the molecule generally
Device or packaging	Could protect a package or dispenser, but not the active ingredient

A patent-number inventory cannot be reliably presented as a current commercial estate without a live jurisdiction-specific patent search. The available commercial record supports the conclusion that hexachlorophene has no meaningful patent-based exclusivity.

How strong is the hexachlorophene patent estate?

The estate is commercially weak. Its principal weaknesses are age, extensive public use, the absence of a differentiated modern delivery system, and the lack of a high-value indication capable of supporting litigation or licensing economics.

Patent strength should be distinguished from regulatory defensibility. A company could theoretically obtain protection for a novel device, concentration, combination, or restricted clinical application. That would not restore broad exclusivity over hexachlorophene itself.

What is the FDA regulatory status of hexachlorophene?

FDA has treated hexachlorophene as a high-risk topical antiseptic rather than a general-purpose consumer ingredient. The agency’s historical actions followed reports of neurological toxicity, particularly when products were applied to premature infants, newborns, damaged skin, or large body surfaces.

The regulatory trajectory was:

Period	Regulatory development
Before 1970s	Broad use in soaps, surgical products, and dermatological preparations
1972	FDA warnings and restrictions after reports of neurotoxicity
1970s onward	Reduced use in infants and limitations on routine antiseptic applications
Subsequent decades	Commercial substitution by chlorhexidine, povidone-iodine, and alcohol products
Current period	No meaningful U.S. growth platform for hexachlorophene

FDA’s historical action against a product does not automatically mean every product containing the ingredient was formally withdrawn for safety. Drug databases may show a discontinued product, a discontinued NDA, or an inactive listing. These classifications must be separated from a formal FDA determination that the active ingredient is unsafe for every use.

The practical regulatory position is unfavorable: any sponsor seeking to revive a hexachlorophene product would face safety, labeling, clinical-justification, and risk-management issues that competing antiseptics do not face to the same degree.

What is the Orange Book status of hexachlorophene?

Hexachlorophene does not have a commercially important current Orange Book position comparable to a protected branded product such as a recent dermatology or hospital-care drug.

The relevant considerations are:

1. A historical pHisoHex listing may exist in FDA product or drug-reference records even if the product is no longer marketed.
2. A discontinued reference product is not equivalent to an actively promoted reference brand.
3. No meaningful patent or regulatory-exclusivity barrier appears to support present-day U.S. pricing.
4. A generic sponsor would still need an approvable pathway, a suitable reference product, and a commercially viable market.

Paragraph IV risk is therefore limited. A Paragraph IV certification is commercially important only when a listed reference product has relevant patents and sufficient demand to justify development or litigation. Hexachlorophene does not present that profile.

Which companies are challenging hexachlorophene?

There is no visible current patent challenge involving a major pharmaceutical company, generic manufacturer, or specialty drug company.

The competitive issue is substitution rather than litigation. Hospitals and clinicians moved away from hexachlorophene toward products with stronger contemporary safety and infection-control acceptance. The principal competitive classes are:

Alternative	Competitive advantage
Chlorhexidine gluconate	Strong hospital presence and broad surgical-preparation use
Povidone-iodine	Established broad-spectrum antiseptic use
Isopropyl or ethyl alcohol	Rapid activity and low-cost formulations
Benzalkonium chloride	Use in selected lower-risk topical products
Modern antimicrobial washes	Better alignment with current institutional protocols

Hexachlorophene is disadvantaged by toxicity concerns, limited indications, weak commercial support, and the absence of a meaningful clinical innovation story.

What formulations are protected by hexachlorophene patents?

The historical commercial format was primarily a topical cleanser or wash, including the 3% pHisoHex product. The formulation itself did not create durable market protection.

Potential formulation concepts include:

• Aqueous antiseptic washes
• Emulsions and liquid cleansers
• Surgical scrub products
• Dermatological preparations
• Combination products with surfactants or emollients
• Controlled-contact or rinse-off delivery systems

These categories are technically accessible and heavily populated by alternative antiseptic technologies. A new hexachlorophene formulation would need to demonstrate a clear benefit in safety, efficacy, tolerability, or a narrowly defined clinical use. A simple reformulation would likely face both patentability and regulatory challenges.

How does hexachlorophene compare with chlorhexidine?

Chlorhexidine has a materially stronger commercial position.

Metric	Hexachlorophene	Chlorhexidine
Current hospital use	Limited	Broad
Safety perception	Unfavorable because of neurotoxicity history	More favorable, although not risk-free
Product innovation	Limited	Multiple concentrations, delivery systems, and combinations
Patent activity	Historically exhausted	Some formulation and delivery patents have supported products
Generic competition	Possible but commercially weak	Established and commercially active
Infection-control adoption	Declining or niche	Embedded in institutional protocols
Revenue potential	Low	Substantial across hospital and consumer channels

Chlorhexidine’s commercial advantage comes from institutional adoption, procedural use, brand and generic availability, and a broader modern product ecosystem. Hexachlorophene cannot compete effectively on price alone because the market has largely moved to other active ingredients.

What financial trajectory does hexachlorophene have?

Hexachlorophene’s financial trajectory is best described as commercial erosion followed by residual niche demand.

Historical phase

The drug had meaningful historical value when antiseptic soaps and surgical cleansers were less differentiated. Its use extended across hospitals, dermatology, and consumer products.

Regulatory contraction

FDA safety actions reduced permissible and accepted use. The loss of infant, routine, and broad consumer applications eliminated important volume segments.

Substitution phase

Chlorhexidine, povidone-iodine, and alcohol-based products captured institutional demand. Those products benefited from modern infection-control protocols and better commercial support.

Residual phase

The remaining opportunity is limited to legacy demand, niche markets, or jurisdictions with different regulatory treatment. Public financial reports do not identify hexachlorophene as a material revenue contributor for current pharmaceutical companies.

No credible basis exists for assigning a current global market size, compound annual growth rate, or branded-product revenue estimate. Hexachlorophene is not a transparent, actively tracked commercial pharmaceutical segment.

What generic launch risks exist for hexachlorophene?

A generic launch would face low patent risk but high commercial and regulatory risk.

Patent risk

Patent barriers appear minimal. A generic sponsor would not be expected to confront a meaningful active composition patent or high-value formulation estate.

Regulatory risk

The sponsor would need to address:

• Safety warnings and restricted use
• Appropriate concentration and route of administration
• Exposure risks on damaged or immature skin
• Labeling for pediatric and neonatal populations
• Evidence supporting the proposed indication
• Reference-product availability and regulatory status

Commercial risk

A low-volume product can be unattractive even when development costs are modest. Manufacturers would face:

• Limited prescriber demand
• Institutional preference for alternatives
• Potential product-liability exposure
• Low reimbursement leverage
• Manufacturing economics that may not support scale

The likely generic scenario is not a rapid branded-to-generic substitution event. It is a low-investment, limited-volume product opportunity, if a regulatory pathway remains practical.

Does hexachlorophene have biosimilar risk?

No. Hexachlorophene is a chemically synthesized small molecule, not a biologic. Biosimilar legislation and biologic exclusivity do not apply.

Any competition would come from generic or authorized-generic topical products, not biosimilars. The principal economic threat is therapeutic substitution by other antiseptic ingredients.

What licensing deals involve hexachlorophene?

There is no prominent current licensing transaction involving hexachlorophene that affects the U.S. pharmaceutical market.

Historical product ownership and distribution arrangements may have changed over the product’s life, but those arrangements do not appear to support a current platform business. The molecule lacks the attributes that normally drive modern licensing:

• No active exclusivity
• No expanding indication set
• No differentiated delivery technology
• No biologic manufacturing complexity
• No high-growth commercial market
• No visible late-stage clinical program

Licensing value would be more likely to arise from a package of legacy brands, manufacturing rights, or regional distribution rights than from the active ingredient itself.

What patent litigation affects hexachlorophene?

No material current U.S. patent litigation involving hexachlorophene is apparent. The absence of litigation is consistent with the expired patent position, limited sales, and lack of a high-value branded product.

Any future dispute would more likely concern:

• Trademark ownership
• Product liability
• Regulatory classification
• Distribution rights
• Contract manufacturing
• A newly developed delivery device or combination product

A conventional Paragraph IV patent case against a major branded hexachlorophene product is unlikely to generate significant commercial exposure.

What generic entry scenarios are most likely?

Three scenarios are commercially plausible:

1. Limited generic re-entry into a narrowly defined prescription topical indication.
2. Continued regional or institutional niche supply without major U.S. market expansion.
3. Further market contraction as hospitals standardize on chlorhexidine and povidone-iodine.

The third scenario is the most consistent with the product’s historical trajectory. A new sponsor would need a clear clinical or economic reason to accept the regulatory and liability burden associated with hexachlorophene.

What geographic markets remain relevant?

The United States is not a strong growth market. Residual relevance may exist in selected international markets where legacy formulations remain registered or where antiseptic procurement practices differ.

Geographic review should assess:

• National product registrations
• Local restrictions on chlorinated phenol antiseptics
• Pediatric labeling requirements
• Hospital procurement standards
• Import and manufacturing controls
• Availability of chlorhexidine and povidone-iodine substitutes

The absence of U.S. exclusivity does not establish unrestricted international commercialization. Each country may impose separate registration, pharmacovigilance, and ingredient restrictions.

Key Takeaways

• Hexachlorophene has no material current U.S. branded pharmaceutical market.
• Its commercial decline followed FDA safety restrictions and substitution by chlorhexidine, povidone-iodine, and alcohol-based antiseptics.
• Original composition and legacy product patents are commercially exhausted.
• No meaningful active U.S. patent estate, Paragraph IV campaign, biosimilar threat, or current patent litigation is apparent.
• The Orange Book relevance of historical hexachlorophene products is limited by discontinuation and weak commercial demand.
• Current financial exposure is likely immaterial for major pharmaceutical companies, with no reliable standalone revenue disclosure.
• Generic entry would face low patent risk but substantial regulatory, liability, and market-adoption risk.
• The remaining opportunity is niche, regional, or institutional rather than a credible high-growth pharmaceutical market.

FAQs About Hexachlorophene Market Value and Exclusivity

Is hexachlorophene still sold in the United States?

Historical products such as pHisoHex are no longer meaningful U.S. commercial products. Limited availability in specialty or legacy channels should not be interpreted as a broad active market.

Can a company still patent a new hexachlorophene product?

A company could seek patents on a genuinely novel formulation, device, combination, or narrowly defined use. It cannot recreate composition-of-matter exclusivity over the old active ingredient.

Is hexachlorophene approved for baby products?

Hexachlorophene use in infants and newborns is heavily restricted because of neurological toxicity concerns. It is not a routine infant antiseptic.

Would a hexachlorophene generic be profitable?

Profitability is doubtful. Patent entry barriers are low, but demand is limited and the product carries regulatory, safety, liability, and substitution risks.

Which drug replaced hexachlorophene in hospitals?

Chlorhexidine became the principal modern hospital substitute in many procedural and antiseptic settings. Povidone-iodine and alcohol-based preparations also captured substantial demand.

References

1. U.S. Food and Drug Administration. (1972). Hexachlorophene: Drug safety communication and restrictions on use. U.S. Department of Health and Human Services.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

4. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. § 250.250: Hexachlorophene-containing preparations. https://www.ecfr.gov/

5. DailyMed. (n.d.). pHisoHex and hexachlorophene topical product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

6. Centers for Disease Control and Prevention. (2002). Guideline for hand hygiene in health-care settings. MMWR Recommendations and Reports, 51(RR-16), 1-44.

7. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term expiration information. https://www.uspto.gov/patents/laws/patent-term-adjustment-patent-term-calculation.